Rhythm Pharmaceuticals, Inc.
MX ˙ BMV ˙ US76243J1051
SecurityMX:RYTM / Rhythm Pharmaceuticals, Inc.
InstitutionPDT Partners, LLC
Latest Disclosed Ownership27,232 shares
Latest Disclosed Value $ 2,368,367
PDT Partners, LLC reports 54.18% decrease in ownership of RYTM / Rhythm Pharmaceuticals, Inc.

On May 15, 2026 - PDT Partners, LLC filed a 13F-HR form disclosing ownership of 27,232 shares of Rhythm Pharmaceuticals, Inc. (MX:RYTM) valued at $2,368,367 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 59,436 shares of Rhythm Pharmaceuticals, Inc.. This represents a change in shares of -54.18% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 27,232 -32,204 -54.18 2,368 -62.78 0.1402
2026-02-17 2025-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 59,436 -26,700 -31.00 6,362 -26.86 0.4126
2025-11-17 2025-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 86,136 -11,502 -11.78 8,699 41.00 0.5485
2025-08-14 2025-06-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 97,638 -4,557 -4.46 6,170 13.97 0.3490
2025-05-15 2025-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 102,195 58,612 134.48 5,413 121.94 0.3844
2025-02-14 2024-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 43,583 32,083 278.98 2,440 305.15 0.2160
2024-11-14 2024-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 11,500 -10 -0.09 602 27.54 0.0534
2024-08-15 2024-06-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 11,510 11,510 473 0.0447
2019-02-14 2018-12-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 0 -17,207 -100.00 0 -100.00
2018-11-14 2018-09-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 17,207 -22,193 -56.33 502 -59.25 0.0208
2018-08-14 2018-06-30 13F RHYTHM PHARMACEUTICALS COM 76243J105 39,400 1,693 4.49 1,232 64.27 0.0468
2018-05-15 2018-03-31 13F RHYTHM PHARMACEUTICALS COM 76243J105 37,707 37,707 750 0.0253
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.